feed
intoler
function
gastrointestin
dysmotil
parenter
nutritionassoci
cholestasi
pnac
common
problem
preterm
verylowbirthweight
vlbw
infant
doubleblind
random
placebocontrol
studi
aim
assess
effect
highdos
oral
erythromycin
prokinet
agent
decreas
incid
pnac
two
secondari
end
point
includ
time
achiev
full
enter
feed
durat
parenter
nutrit
also
evalu
method
infant
consecut
admit
neonat
unit
random
receiv
erythromycin
mgkgdose
everi
hour
day
equival
volum
normal
salin
placebo
attain
less
half
total
daili
fluid
intak
mlkgday
milk
feed
day
life
result
vlbw
infant
enrol
receiv
erythromycin
incid
pnac
significantli
lower
erythromycintr
infant
compar
placebo
infant
p
treat
infant
achiev
full
enter
nutrit
significantli
earlier
mean
se
day
p
durat
parenter
nutrit
also
significantli
decreas
day
p
importantli
fewer
infant
receiv
erythromycin
episod
septicemia
n
compar
placebo
patient
n
p
seriou
advers
effect
associ
erythromycin
treatment
conclus
highdos
oral
erythromycin
consid
rescu
measur
vlbw
infant
fail
establish
adequ
enter
nutrit
anatom
obstruct
patholog
gastrointestin
tract
exclud
abbrevi
use
paper
hida
hepatobiliari
iminodiacet
acid
nec
necrot
enterocol
nicu
neonat
intens
care
unit
pnac
parenter
nutritionassoci
cholestasi
vlbw
low
birth
weight
ilk
intoler
associ
nonanatom
obstruct
ie
function
gastrointestin
dysmotil
common
feed
problem
preterm
verylowbirthweight
vlbw
g
infant
clinic
entiti
believ
consequ
ineffect
infrequ
uncoordin
bowel
activ
secondari
immatur
gastrointestin
tract
difficulti
accur
interpret
clinic
sign
symptom
relat
feed
intoler
constant
fear
necrot
enterocol
nec
gastrointestin
perfor
associ
commonli
use
drug
corticosteroid
prostaglandin
inhibitor
often
result
unnecessari
prolong
usag
parenter
nutrit
longterm
hyperaliment
associ
increas
risk
morbid
lifethreaten
complic
parenter
nutritionassoci
cholestasi
pnac
recurr
septicemia
biochem
ricket
nutrit
defici
pain
well
anesthet
risk
repeat
intraven
long
line
insert
prokinet
agent
enhanc
gastrointestin
motil
may
benefici
infant
promot
enter
feed
reduc
durat
parenter
nutrit
associ
advers
effect
report
seri
preterm
infant
success
treat
oral
erythromycin
refractori
gastrointestin
dysmotil
affirm
experi
led
us
perform
preliminari
random
control
trial
rct
demonstr
oral
erythromycin
introduc
day
life
effect
facilit
enter
feed
vlbw
infant
moder
sever
gastrointestin
dysmotil
importantli
nonsignific
trend
suggest
infant
prolong
feed
intoler
develop
pnac
placebo
group
oral
erythromycin
group
howev
much
controversi
concern
use
oralintraven
erythromycin
promot
enter
feed
preterm
infant
date
limit
number
rel
small
rct
perform
addit
consid
shorten
durat
achiev
full
enter
feed
alon
suffici
reason
recommend
use
prokinet
treatment
vlbw
infant
without
definit
improv
associ
clinic
outcom
pnac
sepsi
complic
secondari
prolong
use
parenter
nutrit
treatment
erythromycin
probabl
clinic
justifi
thu
far
none
publish
report
includ
preliminari
trial
adequ
statist
power
address
critic
issu
therefor
extend
origin
studi
evalu
impact
erythromycin
import
clinic
outcom
primari
object
rct
evalu
whether
use
high
antimicrobi
dose
oral
erythromycin
rescu
treatment
gastrointestin
dysmotil
abl
decreas
incid
pnac
vlbw
infant
furthermor
secondari
object
first
estim
precis
benefit
oral
erythromycin
prokinet
agent
promot
enter
feed
second
determin
whether
use
oral
erythromycin
shorten
durat
requir
parenter
nutrit
acquir
inform
enabl
neonat
clinician
defin
better
use
oral
erythromycin
prokinet
agent
vulner
infant
reduct
incid
pnac
number
day
parenter
nutrit
would
greatli
improv
wellb
preterm
infant
could
also
translat
substanti
save
hyperaliment
need
investig
prolong
cholestat
jaundic
vlbw
infant
consecut
admit
neonat
intens
care
unit
nicu
princ
wale
hospit
hong
kong
time
period
novemb
may
phase
august
septemb
phase
satisfi
inclus
exclus
criteria
elig
recruit
studi
phase
studi
repres
period
patient
recruit
preliminari
rct
phase
studi
compris
period
subsequ
recruit
extend
trial
gap
period
nonrecruit
time
taken
plan
phase
studi
appli
extern
fund
continu
research
project
inclus
exclus
criteria
recruit
period
ident
brief
inclus
criteria
preterm
infant
birth
weight
g
receiv
less
half
total
daili
fluid
intak
mlkgday
milk
feed
oral
rout
day
postnat
age
parent
consent
enter
studi
infant
exclud
follow
lethal
congenit
abnorm
chromosom
disord
congenit
cyanot
heart
diseas
anatom
obstruct
gastrointestin
patholog
intestin
malrot
without
volvulu
stenosi
atresia
gastroschisi
exomphalo
hirschsprung
diseas
nec
undergon
major
gastrointestin
surgeri
within
first
day
life
studi
approv
clinic
research
ethic
committe
chines
univers
hong
kong
phase
phase
studi
written
parent
consent
obtain
random
enrol
case
phase
studi
retrospect
review
incid
pnac
vlbw
infant
nicu
cholestat
jaundic
convent
defin
serum
conjug
bilirubin
concentr
mmoll
ie
mgdl
newborn
although
cutoff
valu
consid
arbitrari
necessarili
correl
specif
hepat
patholog
extens
use
neonat
studi
incid
pnac
vlbw
infant
fail
attain
half
expect
volum
enter
feed
day
past
consecut
year
found
vari
made
assumpt
decreas
incid
introduc
oral
erythromycin
determin
infant
would
requir
arm
ie
total
infant
rct
detect
signific
differ
level
power
experi
phase
studi
indic
could
recruit
infant
gastrointestin
dysmotil
within
period
month
expect
complet
recruit
extra
infant
within
period
manag
enrol
full
quota
patient
month
phase
studi
delay
like
due
substanti
drop
admiss
nicu
princ
wale
hospit
sever
acut
respiratori
syndrom
sar
outbreak
march
hong
kong
admit
sickest
preterm
infant
born
mother
sarsassoci
coronaviru
infect
nicu
statist
suggest
gener
public
took
least
month
regain
confid
give
birth
princ
wale
hospit
henc
could
explain
slight
delay
recruit
process
vlbw
infant
satisfi
entri
criteria
randomli
assign
comput
minim
program
day
receiv
either
oral
erythromycin
placebo
solut
normal
salin
research
assist
involv
clinic
care
infant
perform
random
minim
predetermin
clinic
paramet
could
potenti
influenc
enter
feed
gestat
age
birth
weight
age
introduct
enter
feed
attend
clinic
team
look
infant
complet
unawar
random
assign
recruit
infant
label
trial
code
number
enter
rout
drug
administr
purpos
chosen
lifethreaten
fatal
cardiac
dysrhythmia
associ
erythromycin
mainli
observ
patient
parenter
rout
drug
deliveri
peak
serum
erythromycin
concentr
intraven
infus
typic
higher
circul
level
achiev
medic
given
oral
safe
dosag
intraven
erythromycin
determin
vlbw
infant
administr
drug
intraven
rout
therefor
best
avoid
oral
erythromycin
commenc
day
life
follow
reason
recent
larg
populationbas
studi
indic
although
earli
exposur
erythromycin
ie
day
life
associ
increas
risk
develop
infantil
hypertroph
pylor
stenosi
evid
suggest
increas
risk
expos
medic
day
postnat
age
second
time
dosag
drug
administr
first
second
phase
studi
third
consid
start
prokinet
treatment
day
life
optim
oral
erythromycin
use
studi
rescu
treatment
thu
adequ
time
allow
assess
sever
gastrointestin
dysmotil
exclud
anatom
bowel
obstruct
nec
omin
gastrointestin
patholog
opt
use
high
antimicrobi
dose
erythromycin
mgkgdose
prefer
lowdos
regim
mgkgdose
follow
previou
clinic
experi
case
seri
studi
preliminari
rct
suggest
highdos
regim
effect
promot
milk
feed
significantli
reduc
time
achiev
full
enter
nutrit
vlbw
infant
higher
dose
erythromycin
shown
shorten
whole
gut
transit
time
facilit
gastric
empti
stimul
postprandi
antroduoden
motor
activ
previou
studi
use
lowdos
regim
often
requir
larg
intraven
load
dose
erythromycin
mgkgday
first
day
treatment
oral
rout
drug
administr
like
associ
lower
serum
concentr
achiev
intraven
rout
patient
random
receiv
activ
treatment
prescrib
erythromycin
eryp
erythromycin
ethylsuccin
dilut
mgml
steril
water
abbott
laboratori
abbott
park
il
mgkg
given
everi
hour
wherea
infant
alloc
receiv
placebo
solut
given
equival
volum
normal
salin
eryp
white
liquid
suspens
activ
drug
placebo
solut
mix
thoroughli
milk
feed
mask
appear
attend
neonat
team
task
perform
design
research
staff
member
involv
daili
clinic
care
infant
furthermor
drug
prepar
identifi
trial
code
number
ensur
effect
blind
drug
treatment
start
day
postnat
age
immedi
random
infant
receiv
cours
treatment
oral
feed
discontinu
start
studi
oral
medic
includ
erythromycin
placebo
solut
suspend
administr
studi
solut
resum
infant
restart
enter
nutrit
phase
studi
use
prokinet
agent
cisaprid
domperidon
metoclopramid
strictli
prohibit
electrocardiographi
perform
immedi
second
week
drug
treatment
assess
qtc
interv
vlbw
infant
routin
start
parenter
nutrit
trophamin
mcgaw
inc
irvin
ca
intralipid
kabi
pharmacia
ab
stockholm
sweden
day
life
accord
unit
guidelin
oral
milk
feed
usual
start
within
first
week
life
usual
day
day
discret
attend
clinic
team
given
intermitt
bolus
graviti
orogastr
tube
start
mlh
attend
nurs
aspir
stomach
everi
hour
measur
gastric
residu
oral
intak
increas
cautious
rate
mlhday
toler
infant
fed
mother
milk
whenev
possibl
preterm
commerci
formula
also
use
mother
permiss
breast
milk
avail
infant
examin
least
twice
day
close
monitor
occurr
regurgitationvomit
diarrhea
abdomin
distent
volum
gastric
residu
strict
protocol
implement
discontinu
restart
enter
feed
attend
clinician
would
consid
discontinu
enter
feed
vomit
signific
regurgit
time
hour
volum
gastric
residu
exceed
half
oral
intak
previou
hour
occas
within
day
clinic
sign
symptom
suggest
nec
sinist
intraabdomin
patholog
repeat
regurgit
result
aspir
pneumonia
oral
feed
togeth
studi
drug
resum
soon
sign
symptom
subsid
end
point
half
threequart
full
enter
feed
defin
achiev
mlkgday
respect
milk
feed
infant
receiv
parenter
nutrit
liver
function
monitor
weekli
discharg
nicu
paramet
revert
back
normal
rang
enrol
infant
assign
trial
code
number
group
patient
monitor
ident
infant
suspect
pnac
derang
hepat
function
week
show
improv
discontinu
parenter
nutrit
subject
investig
pair
serolog
titer
hepat
b
c
toxoplasmosi
rubella
cytomegaloviru
herp
viru
type
torch
syphili
perform
urin
sampl
collect
cytomegaloviru
shell
vial
cultur
infant
also
ultrasound
assess
liver
biliari
structur
prime
phenobarbiton
suspici
abnorm
scan
subject
tc
hepatobiliari
iminodiacet
acid
hida
scan
biliari
atresia
could
rule
radiolog
test
liver
biopsi
andor
oper
cholangiographi
recommend
algorithm
investig
neonat
liver
diseas
prolong
conjug
hyperbilirubinemia
guidelin
nicu
strictli
enforc
studi
period
stool
sampl
microbiolog
cultur
collect
studi
infant
immedi
treatment
day
medic
week
treatment
termin
specimen
cultur
wide
rang
select
cultur
media
previous
describ
brief
cultur
media
includ
follow
deoxychol
citrat
agar
thiosulph
citrat
bile
sucros
agar
macconkey
agar
selenitef
enrich
broth
subcultur
onto
deoxychol
citrat
agar
incub
incub
aerob
hour
blood
agar
supplement
vitamin
cycloserin
cefoxitin
fructos
agar
incub
anaerob
hour
skirrow
agar
incub
microaerophil
condit
hour
sabouraud
dextros
agar
incub
aerob
hour
stool
pathogen
includ
salmonella
speci
shigella
speci
thermophil
campylobact
speci
vibrio
speci
identifi
use
standard
biochem
test
api
system
biomerieux
marcyi
etoil
franc
serolog
test
appropri
predomin
pure
growth
aerob
anaerob
fungi
record
microbiologist
perform
stool
cultur
unawar
random
assign
microbiolog
test
howev
discontinu
outbreak
sar
march
heavi
workload
laboratori
restructur
servic
thu
initi
infant
infant
erythromycin
placebo
group
respect
microbiolog
test
perform
look
chang
pattern
bacteri
colon
bowel
demograph
data
clinic
characterist
infant
summar
tabl
detail
enter
feed
includ
time
random
achiev
half
threequart
full
enter
feed
type
milk
feed
durat
parenter
nutrit
potenti
advers
effect
complic
associ
drug
treatment
prolong
hyperaliment
incid
infantil
hypertroph
pylor
stenosi
cardiac
dysrhythmia
electrocardiograph
qtc
interv
oral
erythromycin
treatment
chang
stool
microbi
flora
monitor
import
clinic
outcom
addit
pnac
includ
sepsi
bronchopulmonari
dysplasia
intraventricular
hemorrhag
nec
durat
hospit
mortal
also
document
fisher
exact
test
mannwhitney
u
test
use
compar
proport
continu
variabl
group
appropri
mixedeffect
model
use
assess
longitudin
data
feed
adjust
individu
random
factor
test
perform
window
version
splu
mathsoft
inc
seattl
wa
mixedeffect
model
fit
use
function
lme
splu
comparison
level
signific
set
result
analyz
intentiontotreat
basi
ninetyf
vlbw
infant
admit
nicu
phase
phase
respect
studi
total
period
month
infant
moder
sever
gastrointestin
dysmotil
enrol
respect
schemat
flow
chart
reveal
detail
recruit
process
figur
ninetyon
infant
receiv
oral
erythromycin
equal
number
receiv
placebo
solut
clinic
characterist
group
summar
tabl
clinic
featur
except
oxygen
index
hour
life
compar
group
erythromycintr
infant
significantli
higher
oxygen
index
placebo
infant
immedi
perinat
period
p
tabl
clinic
outcom
summar
tabl
incid
pnac
significantli
higher
placebo
infant
oral
erythromycin
group
infant
p
investig
cholestat
jaundic
indic
infant
placebo
group
infect
cytomegaloviru
infant
posit
urinari
excret
viru
anoth
infant
oral
erythromycin
group
fail
tc
hida
scan
suspect
biliari
atresia
parent
latter
infant
refus
oper
cholangiographi
liver
biopsi
patient
recov
unev
achiev
full
enter
feed
discontinu
parenter
nutrit
inclus
exclus
case
significantli
alter
overal
outcom
pnac
although
overal
maximum
serum
total
bilirubin
conjug
bilirubin
concentr
differ
significantli
group
maximum
serum
alanin
aminotransferas
concentr
significantli
higher
infant
receiv
placebo
solut
p
tabl
significantli
placebo
infant
infant
abnorm
elev
serum
alanin
aminotransferas
concentr
normal
rang
iul
compar
erythromycintr
patient
infant
p
mixedeffect
model
use
analyz
longitudin
data
feed
adjust
first
day
milk
introduct
result
indic
vlbw
infant
abl
achiev
half
threequart
full
enter
nutrit
mean
significantli
decreas
day
p
tabl
number
infant
cultur
proven
septicemia
similar
oral
erythromycin
n
placebo
group
n
tabl
nine
infant
erythromycin
placebo
group
develop
septicemia
treatment
period
respect
howev
significantli
fewer
infant
receiv
oral
erythromycin
episod
septicemia
n
compar
placebo
counterpart
n
tabl
predomin
growth
organ
stool
cultur
immedi
week
drug
treatment
summar
tabl
evid
suggest
outbreak
infect
emerg
multidrugresist
organ
studi
period
import
outcom
includ
bronchopulmonari
dysplasia
defin
oxygen
requir
day
week
postconcept
age
without
includ
death
case
nec
periventricular
hemorrhag
durat
hospit
number
death
case
differ
significantli
group
also
signific
increas
potenti
advers
effect
associ
oral
erythromycin
treatment
prolong
qtc
interv
cardiac
dysrhythmia
emerg
specif
group
resist
organ
bowel
flora
case
infantil
hypertroph
pylor
stenosi
observ
either
group
first
rct
erythromycin
address
issu
clinic
outcom
vlbw
infant
find
suggest
use
highdos
oral
erythromycin
rescu
measur
gastrointestin
dysmotil
preterm
vlbw
infant
could
significantli
reduc
incid
pnac
time
reach
full
enter
feed
need
hyperaliment
incid
recurr
septicemia
also
significantli
decreas
pnac
defin
serum
conjug
bilirubin
concentr
mmoll
common
problem
estim
occur
vlbw
infant
gastrointestin
dysmotil
nicu
preval
current
studi
within
rang
estim
result
suggest
incid
pnac
placebo
group
doubl
compar
infant
treat
erythromycin
thu
number
vlbw
infant
gastrointestin
dysmotil
need
treat
prevent
case
pnac
estim
ci
result
repres
robust
treatment
effect
contrast
pnac
caus
surgicalinduc
short
gut
syndrom
intestin
failur
infant
usual
prolong
parenter
nutrit
result
hepat
failur
death
advanc
liver
injuri
associ
gastrointestin
dysmotil
prematur
infrequ
observ
could
confirm
mild
modest
increas
serum
alanin
aminotransferas
margin
signific
increas
conjug
bilirubin
concentr
howev
import
note
significantli
infant
placebo
group
abnorm
rais
alanin
aminotransferas
level
indic
degre
hepat
damag
tabl
furthermor
clinic
sign
biochem
paramet
may
sometim
deceiv
indic
necessarili
correl
close
diseas
sever
late
stage
deterior
rapid
decompens
hepat
function
occur
unexpectedli
rel
short
cours
parenter
nutrit
one
infant
placebo
group
develop
lifethreaten
hepat
failur
markedli
derang
clot
profil
portal
hypertens
esophag
varic
frank
hematemasi
infant
also
multipl
patholog
fractur
secondari
osteopenia
substrat
defici
ricket
yet
surviv
toler
full
enter
feed
cessat
hyperaliment
date
definit
treatment
pnac
apart
stop
parenter
nutrit
solut
arrest
progress
liver
diseas
achiev
full
enter
nutrit
soon
practic
predict
hepat
function
affect
infant
revers
recov
within
month
stop
parenter
nutrit
result
also
suggest
use
oral
erythromycin
would
significantli
shorten
requir
hyperaliment
day
find
could
translat
substanti
save
human
resourc
cost
prepar
parenter
nutrit
importantli
infant
exposur
complic
intravascular
line
repeat
trauma
line
insert
recurr
sepsi
princip
organ
respons
septicemia
current
previou
studi
preterm
infant
coagulaseneg
staphylococci
tabl
colon
indwel
line
microorgan
common
repeat
infus
bactericid
activ
phagocytosi
intracellular
kill
coagulaseneg
staphylococci
neutrophil
defect
longterm
parenter
nutrit
shorten
need
hyperaliment
elimin
intravascular
line
could
respons
signific
decreas
incid
recurr
septicemia
erythromycintr
infant
recurr
sepsi
presenc
pnac
could
result
rapid
deterior
hepat
function
damag
liver
parenchyma
inhibit
hepatocellular
bile
acid
transport
activ
hepat
macrophag
via
local
produc
procholestat
cytokin
tumor
necrosi
factor
thu
decreas
recurr
sepsi
could
addit
benefit
interrupt
viciou
cycl
caus
intrahepat
cholestasi
destruct
liver
tissu
accord
previou
find
vlbw
infant
function
gastrointestin
dysmotil
achiev
half
threequart
full
enter
feed
significantli
earlier
treatment
highdos
oral
erythromycin
compar
placebo
nonetheless
controversi
concern
effect
erythromycin
promot
enter
feed
date
rct
report
english
literatur
use
erythromycin
prophylact
prokinet
agent
rescu
treatment
prophylact
studi
rct
reveal
benefit
third
studi
oei
lui
demonstr
erythromycintr
infant
significantli
fewer
episod
larg
residu
gastric
aspir
abl
attain
full
oral
feed
quickli
prophylact
studi
natur
howev
necessarili
reflect
efficaci
erythromycin
prokinet
agent
infant
protract
feed
intoler
specif
target
treatment
five
rct
use
erythromycin
rescu
treatment
preterm
newborn
feed
intoler
two
trial
includ
preliminari
rct
found
erythromycin
benefici
previou
studi
use
highdos
mgkg
everi
hour
day
current
trial
reveal
oral
erythromycin
could
shorten
time
achiev
full
enter
nutrit
nonsignific
trend
increas
risk
develop
pnac
placebo
infant
recent
studi
nuntnarumit
et
al
also
suggest
use
intermedi
dose
oral
erythromycin
mgkg
everi
hour
day
follow
mgkg
everi
hour
next
day
could
significantli
reduc
number
withheld
feed
time
full
feed
contrast
lowdos
rescu
treatment
mgkg
administ
everi
hour
intraven
mgkgday
given
oral
use
facilit
enter
feed
two
latter
trial
small
involv
patient
group
therefor
might
adequ
statist
power
detect
subtl
differ
feed
third
rct
infant
protract
feed
intoler
mean
time
attain
full
enter
feed
rang
day
erythromycin
placebo
group
respect
investig
conclud
larger
rct
would
warrant
address
import
issu
anoth
plausibl
explan
discrep
result
studi
could
relat
differ
dosag
use
possibl
higher
dosag
ie
intermedi
high
dose
requir
effect
stimul
gastrointestin
tract
prokinet
agent
cisaprid
metoclopramid
use
promot
gastrointestin
motil
andor
treatment
gastroesophag
reflux
infanc
howev
small
number
rct
perform
cisaprid
preterm
infant
number
particip
involv
studi
rel
small
although
studi
suggest
cisaprid
might
improv
feed
toler
other
unabl
confirm
benefit
furthermor
latter
trial
demonstr
signific
advantag
reduc
daili
total
gastric
aspir
time
establish
full
enter
feed
chang
even
delay
gastric
empti
time
whole
gut
transit
time
addit
seriou
advers
effect
includ
qt
prolong
lifethreaten
arrhythmia
increas
thick
pyloru
muscl
observ
even
fewer
data
avail
metoclopramid
young
infant
one
case
seri
suggest
metoclopramid
might
potenti
use
infant
regurgit
gastroparesi
follow
abdomin
surgeri
gastroparesi
associ
prematur
although
exact
mechan
erythromycin
facilit
advanc
enter
feed
fulli
understood
substanti
evid
suggest
prokinet
action
mediat
via
motilin
pathway
princip
level
stomach
proxim
small
bowel
stimul
pathway
result
increas
proxim
gastric
tone
greater
amplitud
frequent
antral
contract
suppress
pylor
contract
consequ
reduc
outlet
resist
increas
frequenc
duoden
contract
recent
studi
indic
presenc
main
type
motilin
receptor
neural
motilin
receptor
cholinerg
neuron
respond
lowdos
mgkg
erythromycin
predominantli
enhanc
phase
iii
migrat
motor
complex
wherea
smooth
muscl
motilin
receptor
respond
higher
dose
erythromycin
mainli
respons
produc
sustain
antral
contract
facilit
antroduoden
coordin
despit
report
suggest
gut
immatur
could
crucial
factor
lack
respons
erythromycin
infant
week
gestat
current
evid
clinic
trial
suggest
could
fulli
explain
bedsid
find
evid
suggest
develop
gastrointestin
neuroendocrin
network
mostli
complet
week
gestat
distribut
motilin
gastrointestin
tract
week
gestat
close
resembl
pattern
distribut
adult
thu
preterm
infant
earli
gestat
alreadi
equip
essenti
anatom
physiolog
apparatu
necessari
proper
function
bowel
addit
exposur
immatur
bowel
milk
exogen
motilin
result
earlier
detect
phase
iii
motor
activ
would
normal
expect
gestat
age
human
studi
case
seri
perform
preterm
infant
week
gestat
demonstr
use
intraven
erythromycin
mgkg
could
significantli
increas
antral
cluster
contract
antral
motil
index
increas
thu
suggest
presenc
function
motilin
receptor
earli
gestat
anoth
studi
group
investig
studi
differ
dose
mg
vs
mg
erythromycin
administ
oral
show
mg
mg
significantli
increas
gastric
empti
propos
decreas
pylor
tone
coupl
increas
tone
proxim
stomach
could
respons
prokinet
effect
recent
crossov
studi
indic
oral
erythromycin
mgkg
everi
hour
enhanc
antral
contractil
increas
whole
gut
transit
time
measur
ultrasonographi
carmin
red
dye
method
respect
contrast
jadcherla
berseth
use
lowdos
oral
erythromycin
mgkg
fail
initi
phase
iii
motor
migrat
complex
patient
week
gestat
could
induc
dosedepend
manner
infant
week
elhennawi
et
al
also
report
rct
lowdos
oral
erythromycin
mgkg
unabl
induc
stronger
frequent
antroduoden
contract
compar
untreat
patient
transit
time
duodenum
anu
similar
group
thu
cumul
evid
suggest
action
erythromycin
promot
enter
feed
probabl
dose
well
age
depend
clinic
data
support
intermedi
high
oral
dose
erythromycin
effect
lower
dose
rescu
treatment
specul
lower
intragastr
dose
probabl
insuffici
provid
adequ
drug
concentr
either
local
system
exert
desir
prokinet
effect
time
introduct
milk
feed
day
median
prior
commenc
erythromycin
use
prokinet
agent
rescu
rather
prophylact
treatment
could
advantag
acceler
allow
time
bowel
matur
gut
may
becom
suscept
prokinet
drug
stimul
major
advers
effect
encount
oral
erythromycin
particular
none
studi
infant
infantil
hypertroph
pylor
stenosi
within
studi
period
rel
low
incid
pylor
stenosi
chines
babi
coupl
erythromycin
administr
earlier
day
life
probabl
minim
risk
develop
complic
thu
far
none
rct
encount
problem
incid
infantil
hypertroph
pylor
stenosi
estim
case
per
live
birth
increas
risk
erythromycin
would
substanti
increas
incid
case
per
livebirth
ie
case
infant
preval
detect
combin
clinic
trial
therefor
effect
erythromycin
infantil
hypertrop
pylor
stenosi
like
small
benefit
probabl
outweigh
risk
three
infant
develop
transient
ventricular
ectop
tabl
infant
erythromycin
group
develop
dysrhythmia
day
administr
prokinet
treatment
wherea
infant
develop
ventricular
ectop
placebo
treatment
patient
recov
spontan
within
hour
onset
definit
caus
found
qtc
interv
drug
administr
similar
group
use
erythromycin
also
associ
increas
risk
nec
preval
nec
nicu
significantli
improv
introduct
new
hand
hygien
measur
remain
low
level
studi
period
importantli
stool
cultur
surveil
show
pattern
microorgan
chang
significantli
erythromycintr
placebo
infant
one
cultur
reveal
methicillinresist
staphylococcu
aureu
placebo
infant
emerg
stenotrophomona
speci
associ
use
carbapenem
antibiot
patient
tabl
outbreak
infect
nec
emerg
multidrugresist
organ
within
studi
period
limit
studi
first
rct
perform
singl
center
result
may
generaliz
nicu
howev
strong
treatment
effect
suggest
data
robust
attend
neonatologist
abl
observ
similar
benefici
effect
popul
one
could
also
argu
major
pnac
case
mild
question
whether
antimicrobi
agent
therapeut
dose
initi
treatment
benign
condit
howev
lifethreaten
case
hepat
failur
observ
studi
period
addit
durat
requir
parenter
nutrit
incid
recurr
septicemia
significantli
decreas
absenc
major
advers
effect
infantil
hypertroph
pylor
stenosi
lifethreaten
cardiac
arrhythmia
justifi
use
oral
erythromycin
rescu
measur
infant
moder
sever
gastrointestin
dysmotil
undoubtedli
futur
develop
new
gener
macrolid
analogu
devoid
antibiot
activ
retain
motilinomimet
properti
would
distinct
advantag
second
much
effort
focus
identifi
multidrugresist
organ
blood
stool
cultur
studi
perform
intens
care
set
howev
convent
microbiolog
cultur
techniqu
might
sensit
enough
detect
subtl
chang
microflora
gastrointestin
tract
recent
studi
suggest
use
broadspectrum
antimicrobi
agent
earli
perinat
period
could
disturb
normal
development
gene
express
impair
matur
bowel
protect
barrier
interfer
proper
format
mucu
gel
layer
overli
gut
epithelium
chang
pattern
microbi
colon
gastrointestin
tract
modul
effect
critic
sucklingwean
transit
period
could
longlast
consequ
chang
microbiota
gut
mucos
barrier
might
potenti
associ
increas
suscept
infect
develop
inflammatori
atop
diseas
later
life
aspect
microbi
genom
analysi
dna
microarray
analysi
would
valu
futur
studi
identifi
alter
bowel
microbiota
longterm
effect
antibiot
gut
microenviron
summari
largest
rct
oral
erythromycin
assess
prokinet
effect
preterm
infant
also
first
studi
assess
clinic
outcom
systemat
find
suggest
use
rescu
highdos
oral
erythromycin
could
effect
reduc
incid
pnac
vlbw
infant
moder
sever
gastrointestin
dysmotil
addit
treatment
also
associ
earlier
time
day
achiev
full
enter
feed
decreas
requir
parenter
nutrit
reduc
number
recurr
septicemia
major
advers
effect
lifethreaten
complic
encount
find
also
demonstr
import
use
medic
appropri
suffici
highdos
rescu
therapi
favor
data
strengthen
confid
neonat
clinician
use
oral
erythromycin
prokinet
agent
moder
sever
case
although
current
evid
suggest
use
oral
erythromycin
antimicrobi
dose
probabl
safe
readili
promot
emerg
multidrugresist
organ
sampl
size
may
still
inadequ
detect
subtl
advers
effect
outcom
longterm
thu
oral
erythromycin
suffici
dosag
consid
day
life
rescu
treatment
preterm
infant
fail
establish
adequ
enter
nutrit
anatom
obstruct
patholog
gastrointestin
tract
exclud
howev
caution
prophylact
routin
use
erythromycin
prokinet
agent
data
prophylact
rct
convinc
safeti
profil
especi
influenc
bowel
microbiota
gut
protect
barrier
need
address
